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38 Mitogen-
ctivated Protein Kinase
Future Target
or Heart Failure Therapy?*
isto Kerkela, MD, PHD,
homas Force, MD
hiladelphia, Pennsylvania
n this issue of the Journal, Bellahcene et al. (1) report that
umor necrosis factor-alpha (TNF-)-induced depression
f contractile function of the heart is mediated by a specific
ntracellular signaling pathway, the p38 mitogen-activated
rotein kinase (MAPK) pathway. Why is this important?
umerous studies have identified proinflammatory cyto-
ines, including TNF-, as potential mediators of the
rogression of congestive heart failure (CHF). Levels of
NF- were first found to be increased in patients with
arkedly advanced heart failure and later found to correlate
ith prognosis (2,3). Following these initial discoveries,
See page 545
ann et al. (4) and Feldman et al. (5), working with mouse
odels over-expressing either TNF- or its receptors in the
eart, respectively, found that activation of TNF- signal-
ng recreated many of the key pathologies of heart failure:
yocyte hypertrophy, remodeling of the extracellular matrix
ith increased fibrosis, and apoptosis. In addition, of direct
elevance to Bellahcene et al. (1), injection of TNF-
roduced a deleterious hemodynamic response similar to
hat seen in septic shock (6), and administration of TNF to
olunteers depressed left ventricular function, resulting in
ypotension (7). These and many other studies raised the
ypothesis that TNF- played a significant role in the
rogression of heart failure.
This hypothesis was tested in recent clinical trials in
atients with heart failure with agents targeting TNF-,
ither by a decoy approach (i.e., preventing interaction of
NF- with the native receptor; etanercept), or by neutral-
zing TNF- with an intravenously administered monoclo-
al antibody (infliximab). Results of the trials were, to say the
east, disappointing, showing either no benefit or worsened
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Center for Translational Medicine, Jefferson Medical College, Philadel-
hia, Pennsylvania. Supported by research funds from the National Institutes ofb
ealth (RO1 HL6737-1 and HL6168-8). Dr. Force received support for laboratory
esearch from Vertex Pharmaceuticals in 2004.utcomes (8). At the moment, agents targeted to neutralize
NF- are in use for rheumatoid arthritis, inflammatory
owel disease, and psoriasis, but physicians are recom-
ended to exercise caution in using etanercept in patients
ith CHF, and use of greater than a 5 mg/kg dose of
nfliximab is contraindicated in patients with New York
eart Association functional class III/IV CHF.
There are several possible explanations for the lack of
enefit of these agents in the treatment of heart failure.
hese include complement fixation on the myocyte cell
embrane following infliximab administration or a stabi-
izing effect of etanercept on TNF-, leading to elevated
irculating levels of the cytokine (8). Alternatively, progres-
ion of CHF may be due to multiple cytokines and not just
NF-, because, for example, interleukin (IL)-6 levels are
lso highly correlated with a poor prognosis (3). Another
ossibility is that TNF- may have beneficial as well as
eleterious effects on the heart. Supporting this concept,
tudies in mice with both TNF receptors knocked out
howed that ischemic injury was increased (9).
Tumor necrosis factor- activates 4 key pathways in the
ell (Fig. 1). These are: 1) a proapoptotic pathway leading to
ctivation of caspase 8; 2) the c-Jun-N-terminal kinase
JNK) pathway that enhances matrix remodeling and, if
ersistently activated, apoptosis; 3) the nuclear factor-B
NF-B) pathway, which indirectly (via JNK inhibition)
nd directly (via induction of antiapoptotic factors) sup-
resses apoptosis, thus serving as a counter-regulator; and 4)
he p38 pathway which depresses contractility and enhances
atrix remodeling and the inflammatory state. Therefore
argeting specific pathways, in theory, might provide a more
elective approach to treating heart failure than targeting
NF- signaling at the TNF-/TNF receptor level, be-
ause cytoprotective NF-B signaling would not be im-
aired yet the inflammatory state and matrix remodeling
ight be reduced and contractility improved. This, of
ourse, is entirely speculative in the absence of any data in
atients with heart failure.
p38 is a signaling molecule that has been exhaustively
tudied since its discovery almost 12 years ago. It is involved
n multiple cellular processes in many types of cells, includ-
ng inflammation, cell growth, and cell death. In the heart,
38 is activated by numerous pathologic stresses, including
schemia (and, to a lesser extent, reperfusion) and pressure
verload, and activation of p38 has been observed in human
earts with advanced heart failure (10,11). Its role in
egulating cardiac hypertrophy remains controversial (12),
ut studies employing both genetic and pharmacologic
nhibition of p38 suggest it plays a key role in left ventricular
xtracellular matrix remodeling (12), in cell survival follow-
ng ischemia-reperfusion (13,14), and, possibly, in post-
yocardial infarction (MI) remodeling (15). These adverse
ffects are mediated, in part, via p38-regulated induction of
nflammatory cytokines. This is accomplished in large part
y p38-mediated activation of mitogen-activated protein
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August 1, 2006:556–8 Editorial Commentinase-activated protein kinase 2 (MK2), which increases
evels of inflammatory cytokines by stabilizing their mes-
enger ribonucleic acid and by enhancing translation (16).
his creates a positive feedback loop wherein inflammatory
ytokines lead to the activation of p38/MK2 which then
ncreases levels of inflammatory cytokines (Fig. 1).
The first clear evidence that p38 activation produced
egative inotropic effects in vivo was provided by Wang
t al. (reviewed in reference 12). Subsequent studies in vitro
howed that adenovirus-mediated gene transfer of an acti-
ated mutant of MKK3, a kinase that directly activates p38,
ed to decreased contractility, and, conversely, pharmaco-
ogic blockade of p38 enhanced contractility in cultured
ardiac myocytes (17). Importantly, this study suggested
hat the negative inotropic effect of p38 is mediated by
ltering myofilament sensitivity to intracellular calcium
oncentration. The negative inotropic effects of p38 have
ince been confirmed in both in vitro and in vivo models.
Bellahcene et al. (1) now show that either genetic
nhibition of p38, achieved by knocking out MKK3, an
pstream activator of p38 (Fig. 1), or pharmacologic inhi-
ition of p38 (with a small molecule inhibitor) attenuate
NF-–induced contractile depression in an isolated per-
used mouse heart model (thereby eliminating contributions
rom the periphery, which can obviously be quite profound
ith TNF-). Importantly, they go even further down the
athway to demonstrate that knocking out the p38 target,
K2, also largely prevents the negative inotropic response
nduced by TNF-, although the authors point out that this
ould be due to the fact that MK2 knockout mice have
educed p38 levels in their hearts. Of note, whereas the
urrent study focuses on early effects of TNF- on cardiac
ontractility, data from numerous in vitro and ex vivo
tudies concur that TNF- and other cytokines produce a
igure 1. A schematic figure showing the multiple pathways activated by
umor necrosis factor-alpha (TNF-) (caspase 8/extrinsic apoptosis path-
ay; nuclear factor-kappa B [NF--B]; c-Jun-N-terminal kinase [JNK];
nd p38) as well as other inputs that activate p38 (e.g., other cytokines and
schemia). Also shown are kinases upstream and downstream of p38, as
ell as biological processes regulated by the various pathways.egative inotropic response with early effects within 30 minnd prolonged effects for up to 48 to 72 h (7). The
echanisms of the late effects are not known.
Most of the clinical trials of small molecule inhibitors of
38 target inflammatory diseases or multiple myeloma.
reclinical studies in models of cardiovascular diseases
uggest that inhibition of p38 might have applications in
schemic diseases, including acute coronary syndromes
ACS), because, as noted, various strategies to block p38
and MK2) activation in MI models were protective (13–
5,18). Inhibitors of p38 are currently in clinical trials for
reatment of stroke (SCIO323) and acute coronary syn-
rome (VX702). In the latter study, patients going to
ercutaneous coronary intervention were treated for 5 days
ith VX702 versus placebo. There was no increase in
dverse events, and serum levels of C-reactive protein
CRP) were reduced by VX702, possibly consistent with an
ntiinflammatory effect in ACS. Intriguingly, CRP levels
emained reduced 4 weeks after the drug had been stopped.
Is there any rationale for the use of p38 inhibitors in heart
ailure patients besides the fact that p38 activity is increased
n the hearts of these patients (10,11)? We believe the
nswer to this question may be a very cautious “yes.” In
ddition to studies supporting beneficial effects on contrac-
ile function and matrix remodeling in animal models, Kyoi
t al. (19) recently reported that inhibition of p38 with
ither of 2 small molecule inhibitors, SB203580 and
R167653, reduced apoptosis, fibrosis, hypertrophy, and
eft ventricular dilatation and increased ejection fraction
nd left ventricular contractility in the cardiomyopathic
amster model. Of note, the proinflammatory effects of p38
re likely mediated by several inflammatory cytokines in
ddition to TNF-, including IL-1- and IL-6 which are
ypothesized to play roles in progression of heart failure.
hus, if the anti-TNF- heart failure studies failed, in part,
ecause cytokines in addition to TNF are involved, p38
nhibition might address that issue more effectively. To our
nowledge, only 1 clinical trial of a p38 inhibitor in patients
ith heart failure has been initiated (with semapimod), but
his trial was apparently stopped when the results of the
NF--targeted heart failure trials were reported. How-
ver, p38 inhibition, if able to be tolerated long term, may
ave the potential to not only increase contractility (1) but
lso to reduce matrix remodeling. Clearly, though, there is
need for much more preclinical work in this area before
roceeding to trials in this complex and fragile patient
opulation.
eprint requests and correspondence: Dr. Thomas Force, Cen-
er for Translational Medicine, Jefferson Medical College, 1025
alnut Street, College Building Room 316, Philadelphia, Penn-
ylvania 19107. E-mail: thomas.force@jefferson.edu.
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